Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Testing Novel Pharmacogenetic and Adherence Optimization Treatments to Improve the Effectiveness of Smoking Cessation Treatments for Smokers With HIV

NCT04176172 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT04176172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04176172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Testing Novel Pharmacogenetic and Adherence Optimization Treatments to Improve the Effectiveness of Smoking Cessation Treatments for Smokers With HIV
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 17, 2020
Completion date
November 30, 2026
Enrollment
340 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv/aids, nicotine dependence